Compare CCEL & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEL | NSRX |
|---|---|---|
| Founded | 1989 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 32.2M |
| IPO Year | 2022 | N/A |
| Metric | CCEL | NSRX |
|---|---|---|
| Price | $3.46 | $3.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 7.5K | ★ 79.9K |
| Earning Date | 04-14-2026 | 03-25-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $25,384,279.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $344.00 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $2.72 | $1.98 |
| 52 Week High | $5.52 | $9.99 |
| Indicator | CCEL | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 49.88 |
| Support Level | $3.18 | $2.04 |
| Resistance Level | $3.57 | $3.48 |
| Average True Range (ATR) | 0.19 | 0.25 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.12 | 34.88 |
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.